OABI · OmniAb, Inc.
$4.87
-0.12 (-2.40%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$670.25M
Shares
145.39M
Volume · Oct 2
1.62M
Avg daily vol (3M)
1.42M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$4.87
Open$5.04
Day$4.81–5.09
52W close$1.36–5.04
Avg vol 30d1.5M
Short int7.1M · 4.9% float · 4.1d
Short vol60%
Last earningsAug 6, 2026
DataSep 2021–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 5, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$38.46M
Trailing 12 months
Net income (TTM)
−$44.27M
Trailing 12 months
Revenue growth YoY
+244.2%
Year over year
Operating margin
-125.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-2.7%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$24.34M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+21.3%
Year over year · more shares
Price change (1Y)
+202.5%
Trailing year
Short interest
4.9%
Latest settlement · 4.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+101%
above
Price vs 50-day avg
+26%
above
RSI (14)
61
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+3%
trailing
6-month return
+234%
trailing
YTD return
+163%
this year
Relative strength
+221%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.90% of float · ▲ +19.1% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
144 holders — mid 3-yr range
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
−29%
Y/Y
EPS growth
+7%
Y/Y
Free cash flow
$-37.0M
Quant / Vol
risk profile
Volatility
76%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
5.9%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 6, 2026
full year 2026
Revenue
Initiated
$32M – $36M
prior FY $18.67M
midpoint +82.1% Y/Y
Costs and operating expenses
Initiated
$84M – $88M
Cash costs and operating expenses
Initiated
$51M – $55M
Effective tax rate
Initiated
0%
end of year 2026
Cash and cash equivalents
$37M – $41M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+101%
Bullish
Price vs 50-day avg
+26%
Bullish
RSI (14)
61
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $4 › 200d $2 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +22 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.90% of float · ▲ +19.1% MoM · 4.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
144 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $5 · 95%
Range high $5
vs 200-day avg +101%
vs 50-day avg +26%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active partners | 110 | Q2 FY2026 | — |
| active programs | 425 | Q2 FY2026 | — |
| Cash costs and operating expenses non-GAAP | $25.5M | the first half of 2026 | — |
| OmniAb-derived programs in clinical development or being commercialized | 34 | Q2 FY2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OABI
this stock
OmniAb, Inc.
|
$670.25M | +163.2% | -29.3% | — | 4.9% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OABI | +5.6% | +2.5% | +233.6% | -1.8% | +163.2% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +5.9% | +3.0% | +221.4% | -2.7% | +150.4% |